GlassScriptPhysician profile
Russell D Anderson
NPI 1801963376
$960.73
in general payments reported to CMS, 2019-2025
16 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $39.09 · 2021: $38.24 · 2022: $18.27 · 2023: $13.13 · 2024: $258 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.99 |
| Education | $168.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $259.96 | 2024-2025 | Enhertu |
| Janssen Biotech, INC. | $109.78 | 2019-2025 | Erleada, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $85.45 | 2019-2025 | Lynparza |
| Celgene Corporation | $78.51 | 2024-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $68.96 | 2019-2025 | Welireg, Keytruda |
| Sobi, INC | $51.12 | 2025 | |
| Eisai INC. | $50.97 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.15 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $47.92 | 2019 | |
| Glaxosmithkline, LLC. | $43.03 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $40.65 | 2019-2023 | |
| Genentech USA, INC. | $18.27 | 2022 | |
| Array Biopharma INC | $17.72 | 2024 | Tukysa, Mektovi, Braftovi |
| Ipsen Biopharmaceuticals, INC | $15.38 | 2025 | Onivyde, Somatuline Depot |
| Amgen INC. | $13.68 | 2025 | Lumakras, Imdelltra (Amg757) |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $10.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.